Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready
Arxada LLC is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. This volume of activity is distributed across 2 distinct examiners and 2 distinct art units, indicating a slightly broader reach within the USPTO's specialized groups. The focus on Biotechnology & Pharmaceuticals often involves complex regulatory and technical hurdles that require precise examiner interactions.
MOU, LIYUAN is the busiest examiner for the portfolio, currently overseeing 2 pending office actions. This concentration of the pending actions under a single examiner suggests that MOU, LIYUAN's preferences and past decisions will significantly influence the overall success of the company's current prosecution efforts. The remaining action is handled by a second distinct examiner, providing a measure of examiner diversity.
The involvement of 2 distinct art units suggests that the company's innovations may span different sub-specialties within the broader biotechnology field. For the practitioner, managing 3 pending office actions across 2 art units requires a strategy that accounts for potentially different examination styles. However, with MOU, LIYUAN handling 2 of these actions, there is an opportunity to leverage consistent arguments across a majority of the pending portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOU, LIYUAN | 2 | 42.9% | +59.0% |
| SASAN, ARADHANA | 1 | 64.5% | +26.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18451355 | Food Contact Disinfecting/Sanitizing Formulation And Wipe | SASAN, ARADHANA | 22d overdue |
| 18551205 | Biocidal Composition and Method | MOU, LIYUAN | — |
| 18551203 | Biocidal Composition and Method | MOU, LIYUAN | — |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18551205 | Biocidal Composition and Method | MOU, LIYUAN | 1628 | §103§112DP | Non-Final OA | — | Pending | Sep 19, 2023 |
| 18551203 | Biocidal Composition and Method | MOU, LIYUAN | 1628 | §103§112DP | Non-Final OA | — | Pending | Sep 19, 2023 |
| 18451355 | Food Contact Disinfecting/Sanitizing Formulation And Wipe | SASAN, ARADHANA | 1615 | Other | Final Rejection | 22d overdue | Pending | Aug 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial